Estrogen receptor in the brain's reward center drives cataplexy-like attacks in narcoleptic mice
In narcolepsy-model mice, estrogen acting on GPER in the nucleus accumbens increased cataplexy-like attacks. Mouse data only, with no human or lifespan evidence.
Summary
In orexin neuron-ablated mice, a model of type 1 narcolepsy, estrogen increased cataplexy-like attacks (sudden muscle-tone loss triggered by positive emotion) in both sexes, and tamoxifen reduced them. In females, attacks peaked at estrus, when plasma estradiol was highest. Pharmacology in male mice pointed to the membrane G protein-coupled estrogen receptor (GPER): a GPER agonist increased attacks, a GPER antagonist reduced them, and ER alpha and ER beta agonists did nothing. The GPER agonist raised c-Fos activation in the nucleus accumbens, and injecting it directly there increased attacks, while dorsal striatum injection had no effect. This is small-sample mouse work on a behavioral count. It shows a plausible brain mechanism linking estrogen to emotion-triggered behavior, but nothing about humans, therapy or lifespan.
Detailed Summary
Estrogen acts in the brain of both sexes, yet how it shapes emotion is poorly understood. This study used cataplexy, a sudden loss of muscle tone triggered by positive emotion in narcolepsy type 1, as a readout of emotion-driven circuit activity. The authors had earlier tied cataplexy to the rostral nucleus accumbens (NAc). They began this work after noticing that tamoxifen, a selective estrogen receptor modulator, reduced attacks.
The mechanism, in plain terms: estrogen appears to switch on GPER, a membrane-bound receptor, on neurons in the NAc. That raises NAc activity and makes emotion-triggered attacks more frequent. Here the mechanism is a pharmacological and c-Fos signal, the function is a behavioral count, and lifespan was not studied.
The experiments used orexin neuron-ablated mice, 8-12 weeks old, with small groups (n = 4-10 per experiment, mostly crossover designs with randomized drug order). Attacks were counted blind to treatment over the 12-hour night. Estradiol raised attacks and tamoxifen lowered them in males and females. Ovariectomized females had fewer attacks than sham controls (16.2 vs 35.3), and tamoxifen did not lower them further. Estradiol still increased attacks after ovariectomy, which argues against a purely reproductive-organ effect. Attacks peaked at estrus, and plasma estradiol was higher at estrus than at diestrus. Chocolate, a known trigger, added to the effect without interacting with estrogen. In males, the GPER agonist G1 increased attacks and the antagonist G15 decreased them, while the ER alpha agonist PPT and ER beta agonist DPN had no effect. Estradiol and G1 increased NAc c-Fos, tamoxifen and G15 decreased it, and most c-Fos-positive cells expressed GPER. Bilateral NAc microinjection of estradiol or G1 increased attacks and G15 decreased them. Dorsal striatum injection of G1 or G15 had no effect.
The implication is a candidate pathway by which sex hormones tune emotion-linked circuits, with possible relevance to cataplexy and mood. The authors suggest NAc GPER as a target, but that is speculation. No sex difference in human narcolepsy incidence is established, and the human link is untested.
Caveats: the mice are a genetic narcolepsy model, group sizes are small, only male mice were used for the receptor and NAc work, and no dose-response was done. The identity of the GPER-expressing neurons and the source of estrogen at the NAc (blood or local aromatase) are unknown. Cataplexy-like behavior is a proxy for positive emotion. Tamoxifen's effect also warns that it may confound Cre-ER studies of behavior.
Key Findings
- Estradiol increased and tamoxifen decreased cataplexy-like attacks in male and female orexin-ablated mice (n = 6-10 per group); ovariectomy lowered baseline attacks.
- Female attacks peaked at estrus, when plasma estradiol was highest, and chocolate added to the effect without an interaction.
- In male mice, GPER agonist G1 raised and antagonist G15 lowered attacks; ER alpha and ER beta agonists had no effect.
- G1 and estradiol raised NAc c-Fos, and NAc microinjection increased attacks, while dorsal striatum injection had no effect (n = 6).
- Mechanism and behavior were measured only in mice; lifespan, human data and dose-response were not studied.
Methodology
Orexin neuron-ablated mice (8-12 weeks, both sexes) were given intraperitoneal or NAc-microinjected estrogen-receptor drugs in randomized crossover designs, with night-time video scoring of cataplexy-like behavior blinded to treatment. Supporting measures included ovariectomy versus sham, vaginal cytology for estrous stage, plasma estradiol ELISA, and c-Fos/GPER immunohistochemistry. Groups were small (n = 4-10), analyzed with repeated-measures ANOVA and Holm-Sidak tests.
Study Limitations
Small mouse groups in a single genetic narcolepsy model; the receptor and NAc experiments used only male mice, and no dose-response was done. Specificity of the cell type (presumably medium spiny neurons), the source of estrogen at the NAc, and contributions of other GPER-rich brain regions remain unresolved. Cataplexy-like behavior is a proxy for emotion, and no human, function-in-aging or lifespan data were gathered.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
